0001493152-23-040499.txt : 20231113 0001493152-23-040499.hdr.sgml : 20231113 20231113161023 ACCESSION NUMBER: 0001493152-23-040499 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231113 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231113 DATE AS OF CHANGE: 20231113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Enveric Biosciences, Inc. CENTRAL INDEX KEY: 0000890821 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 954484725 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38286 FILM NUMBER: 231398774 BUSINESS ADDRESS: STREET 1: 4851 TAMIAMI TRAIL N, SUITE 200 CITY: NAPLES STATE: FL ZIP: 34103 BUSINESS PHONE: 239-302-1707 MAIL ADDRESS: STREET 1: 4851 TAMIAMI TRAIL N, SUITE 200 CITY: NAPLES STATE: FL ZIP: 34103 FORMER COMPANY: FORMER CONFORMED NAME: AMERI Holdings, Inc. DATE OF NAME CHANGE: 20150527 FORMER COMPANY: FORMER CONFORMED NAME: SPATIALIZER AUDIO LABORATORIES INC DATE OF NAME CHANGE: 19950323 8-K 1 form8-k.htm
false 0000890821 0000890821 2023-11-13 2023-11-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

Current Report

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): November 13, 2023

 

ENVERIC BIOSCIENCES, INC.

(Exact name of Registrant as specified in its charter)

 

Delaware   001-38286   95-4484725

(State or other jurisdiction

of incorporation)

  

(Commission

File No.)

  

(IRS Employer

Identification No.)

 

Enveric Biosciences, Inc.

4851 Tamiami Trail N, Suite 200

Naples, FL 34103

(Address of principal executive offices and zip code)

 

Registrant’s telephone number, including area code: (239) 302-1707

 

 

(Former name or former address, if changed since last report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
     
  ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
     
  ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
     
  ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common stock, par value $0.01 per share   ENVB   The Nasdaq Stock Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.02 Results of Operations and Financial Condition.

 

On November 13, 2023, Enveric Biosciences, Inc. issued a press release providing a corporate update and announcing its financial results for the third quarter ended September 30, 2023. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.

 

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, that is furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

 

Item 9.01 Financial Statements and Exhibits.

 

(d) Exhibits.

 

Exhibit No.

   Description
     
99.1   Press Release, dated November 13, 2023
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ENVERIC BIOSCIENCES INC.
     
Date: November 13, 2023 By: /s/ Joseph Tucker
    Joseph Tucker
    Chief Executive Officer

 

 

 

 EX-99.1 2 ex99-1.htm

 

Exhibit 99.1

 

 

Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial Results

 

EVM-301 Series

 

  ● Presented and published leading scientific research describing development and screening methods for non-hallucinogenic, neuroplastogenic drug candidates in Enveric’s EVM301 Series of candidates targeting the treatment of mental health disorders
  ● Announced AI-powered drug candidate generation engine surpassed 1000 compounds discovered and analyzed in Psybrary™ portfolio of psychedelic-inspired therapeutic candidates
  ● Published research describing a key cane toad enzyme and its application to the biosynthesis of novel indolethylamine-type drug candidates with potential use in psychiatric medicine
  ● Granted U.S. Patent (USPTO No. 11,752,130) providing claims to novel composition of matter and pharmaceutical drug formulations for a family of carboxylated derivatives of tryptamine-based drug candidates

 

EB-373

 

  ● Granted U.S. Patent (USPTO No. 11,707,447) encompassing novel compositions of matter and pharmaceutical drug formulations for prodrugs utilizing C4-carbonothioate-substituted tryptamine derivative compounds
  ● Reported results from preclinical studies exploring the metabolic profile and the safety of lead candidate EB-373, a next generation psilocin prodrug targeting psychiatric disorders
  ● Highlighted results from animal studies demonstrating oral bioavailability and favorable safety profile for EB-373
  ● Completed manufacturing of EB-373 to supply drug material for completion of preclinical program

 

CAMBRIDGE, Mass., November 13, 2023 – Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders, today provided a corporate update and reported financial results for the third quarter of 2023 ended September 30, 2023.

 

 

 

 

“The third quarter of 2023 was a period of significant progress for our team as we completed several initiatives that served to enhance the value of our differentiated neuroplastogenic small-molecule therapeutics as we advance towards the clinic,” said Joseph Tucker, Ph.D., Director and CEO of Enveric. “Key to this effort, we significantly strengthened our IP estate across our development portfolio, highlighted by new patents from the United States Patent and Trademark Office (USPTO) for our EVM301 Series of novel non-hallucinogenic molecules and for EB-373, our lead EVM201 Series prodrug product candidate. The patents encompass composition of matter and pharmaceutical drug formulations related to the EVM301 Series and composition of matter and pharmaceutical drug formulations pertaining to EB-373. Additionally, we filed six non-U.S. applications related to the EVM301 Series, received several U.S. Notices of Allowance for claims related to the EVM301 Series and EB-373, and filed a new application for our AI-based computational methods for identifying and optimizing novel tryptamine derivatives. Our expectation is the USPTO will grant patents based on the Notices of Allowance, which would continue to increase the value of our technologies and further distinguish Enveric’s science as groundbreaking and unique.”

 

Dr. Tucker added: “Through the third quarter of 2023 and into Q4, we have showcased the leading drug discovery and research engine behind our EVM301 Series of compounds, with several publications and presentations in academic settings, establishing a leading position in the psychedelic and psychedelic-inspired drug development industry to deliver next-generation treatments, with low- and non-hallucinogenic compounds. We look forward to several key milestones during the remainder of 2023, including identification of a lead candidate from the EVM301 Series by year-end. With this lead candidate identified, we anticipate initiating a thorough and expedited preclinical development program in 2024 in preparation for an Investigational New Drug application.”

 

“As part of our objective to ensure clinical readiness, the third quarter was also characterized by completing key manufacturing and preclinical activities needed to file for regulatory clearance to begin a first in human clinical trial of EB-373. We announced favorable results from exploratory animal studies, which demonstrated oral bioavailability and well-tolerated side effects for EB-373. The outcome of these animal studies indicated potential for EB-373 to reduce GI upset and vomiting as well as rapid onset of action and systemic clearance, improving on the pharmacokinetic characteristics of psilocybin. Additionally, further preclinical work assessing absorption, distribution, metabolism, and excretion (ADME) assays demonstrated rapid conversion of EB-373 to the active metabolite psilocin,” concluded Dr. Tucker.

 

THIRD QUARTER AND RECENT PROGRAM UPDATES

 

  ● Presented and published leading scientific research describing development and screening methods for non-hallucinogenic, neuroplastogenic drug candidates in Enveric’s EVM301 Series of candidates targeting the treatment of mental health disorders
  ● Showcased drug candidate generation engine surpassing 1000 compounds discovered and analyzed in Psybrary™ Portfolio of psychedelic-inspired therapeutic candidates

 

 

 

 

  ● Published research describing a key cane toad enzyme and its application to the biosynthesis of novel indolethylamine-type drug candidates with potential use in psychiatric medicine
  ● Reported results from preclinical studies exploring the metabolic profile and the safety of lead candidate EB-373, a next generation psilocin prodrug targeting psychiatric disorders. Reported favorable preclinical absorption, distribution, metabolism, and excretion (ADME) and toxicology assays demonstrated rapid conversion of EB-373 to the active metabolite psilocin
  ● Completed manufacturing of EB-373 to supply drug material for completion of preclinical program with resulting high purity of prodrug product that allows Enveric and partners to ship EB-373 without being subject to restrictions required for controlled substances
  ● Continued to drive value with growing IP portfolio across therapeutic pipeline and filed provisional patent application to support AI-based computational methods for identifying and optimizing novel tryptamine derivatives

 

  ○ Granted USPTO No. 11,707,447 encompassing compositions of matter and pharmaceutical drug formulations for prodrugs utilizing C4-substituted tryptamine derivatives and C4-carbonothiate-substituted tryptamine derivatives
  ○ Granted USPTO No. 11,752,130 providing claims to novel composition of matter and pharmaceutical drug formulations for a family of carboxylated derivatives of tryptamine-based drug candidates

 

THIRD QUARTER 2023 FINANCIAL RESULTS

 

Net loss attributable to shareholders was $2.82 million for the third quarter ended September 30, 2023, including $0.16 million in net non-cash income, with a basic and diluted loss per share of $1.30, as compared to a net loss of $2.60 million and non-cash income of $2.29 million, with primary and diluted loss per share of $1.46 per share for the quarter ended September 30, 2022.

 

Net cash used in operations for the quarter ended September 30, 2023, was $2.98 million, consisting of a $2.82 million net loss, adjusted by a net of $0.16 million in non-cash income and changes in asset and liability balances of $0.23 million.

 

As of September 30, 2023, the Company had cash and cash equivalents of $4.27 million.

 

About Enveric

 

Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, and addiction disorders. Leveraging its unique discovery and development platform, Psybrary™, Enveric has created a robust intellectual property portfolio of New Chemical Entities for specific mental health indications. Enveric’s lead program, the EVM201 Series, comprises next generation synthetic prodrugs of the active metabolite, psilocin. Enveric is developing the first product from the EVM201 Series – EB-373 – for the treatment of psychiatric disorders. Enveric is also advancing its second program, the EVM301 Series, expected to offer a first-in-class, new approach to the treatment of difficult-to-address mental health disorders, mediated by the promotion of neuroplasticity without also inducing hallucinations in the patient. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit www.enveric.com.

 

 

 

 

Forward-Looking Statements

 

This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as “plans,”“ expects” or “does not expect,” “proposed,” “is expected,” “budgets,” “scheduled,” “estimates,” “forecasts,” “intends,” “anticipates” or “does not anticipate,” or “believes,” or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, would, or might occur or be achieved. Forward-looking statements may include historical statements and statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: carry out successful clinical programs in Australia; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations on the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric’s products, including patent protection; identify and pursue alternative routes to capture value from its cannabinoid clinical development pipeline assets; the ability to continue as a going concern; manage its future growth effectively; achieve the intended benefits of the cost reduction plan to the extent or as quickly as anticipated; transition from third-party service providers supporting R&D efforts to internal science teams without any adverse impact on Enveric’s ongoing and planned clinical trials; and engage the cost reduction plan efforts without negatively impacting Enveric’s business operations and reputation.

 

A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric’s filings with the Securities and Exchange Commission, including Enveric’s Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

 

Contact

 

Investor Relations

 

Tiberend Strategic Advisors, Inc.

Daniel Kontoh-Boateng

(862) 213-1398

dboateng@tiberend.com

 

Media Relations

 

Tiberend Strategic Advisors, Inc.

Casey McDonald

(646) 577-8520

cmcdonald@tiberend.com

 

 

 

 GRAPHIC 3 ex99-1_001.jpg begin 644 ex99-1_001.jpg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end EX-101.SCH 4 envb-20231113.xsd XBRL SCHEMA FILE 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 5 envb-20231113_lab.xml XBRL LABEL FILE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 6 envb-20231113_pre.xml XBRL PRESENTATION FILE XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Nov. 13, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Nov. 13, 2023
Entity File Number 001-38286
Entity Registrant Name ENVERIC BIOSCIENCES, INC.
Entity Central Index Key 0000890821
Entity Tax Identification Number 95-4484725
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One Enveric Biosciences, Inc.
Entity Address, Address Line Two 4851 Tamiami Trail N
Entity Address, Address Line Three Suite 200
Entity Address, City or Town Naples
Entity Address, State or Province FL
Entity Address, Postal Zip Code 34103
City Area Code (239)
Local Phone Number 302-1707
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common stock, par value $0.01 per share
Trading Symbol ENVB
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 form8-k_htm.xml IDEA: XBRL DOCUMENT 0000890821 2023-11-13 2023-11-13 iso4217:USD shares iso4217:USD shares false 0000890821 8-K 2023-11-13 ENVERIC BIOSCIENCES, INC. DE 001-38286 95-4484725 Enveric Biosciences, Inc. 4851 Tamiami Trail N Suite 200 Naples FL 34103 (239) 302-1707 false false false false Common stock, par value $0.01 per share ENVB NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://enveric.com/role/Cover Cover Cover 1 false false All Reports Book All Reports envb-20231113.xsd envb-20231113_lab.xml envb-20231113_pre.xml form8-k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "form8-k.htm": { "nsprefix": "ENVB", "nsuri": "http://enveric.com/20231113", "dts": { "schema": { "local": [ "envb-20231113.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "envb-20231113_lab.xml" ] }, "presentationLink": { "local": [ "envb-20231113_pre.xml" ] }, "inline": { "local": [ "form8-k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://enveric.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-11-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-11-13", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "span", "p", "body", "html" ], "reportCount": 1, "baseRef": "form8-k.htm", "first": true, "unique": true } } }, "tag": { "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://enveric.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001493152-23-040499-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001493152-23-040499-xbrl.zip M4$L#!!0 ( $J!;5<>4'. )P, . + 1 96YV8BTR,#(S,3$Q,RYX M],_T'UNS&&)@T$TFE(:)F2-!-R:U\ZLKV BBTYD@PD7U_) M-RX&%VC+D[1[SME=:5>F]7$>^&@*7!!&VX9=J1H(J,L\0D=MXWY@?AIT>CT# M?3Q[^P:I7^N=::(N =]KH@OFFCTZ9*?H&@?01)^! L>2\5/T@/U(6UB7^,!1 MAP6A#Q*4(XG41$>56M5!IKF#[@-0C_'[VUZN.Y8R%$W+FLUF%,;X1%1< M%NPF.)!81B)7J\ZKZ6\W^A41;DYN'%^%XL/\ECR-@)Y$%YC.Q"/^V@V$*%Q-1=P7LR)RR#CZS$N0(E&Z''"91D4 _6< +50^%H] M T;"'&$8X%JD:*N+HE M8Y!MVPH(/@1 99?QX *&./)5'L\1]LF0@&<@B?D(I.XQ$6(7RL6R/L64,M7. M:J92B[:%(5']FAN42=]ODS,?[E3B2"_4/&V,H'U6ARF#@8C7-I+EDE:FYL&0 M4!)'3L?'1J8>ED@7J98QLV6M@XM*D0#O&SV+UR$'H>AQ17UE2/DII)SK8M^- M_(.HB_S*F*D].\?" 6=3= M#%$]?4_=)VQ!$OW]&:AMS&+8-=>:.F5WG3U5V M1?51!M$12J8OOJ/UDTH#9Q*8NP65PNN@1%@(7!+5S$M/0)(ZD9I^LQ0&Z3C" M0-8_K-S'SKZ5*PKX_['DOM8OUMJR5@=+[=>'KZ7*95PB6ACBLB?S[S(VE M2BAZ9V8\4YM,NV;6[(M,]TEB<0+[)9'Q#DABRT.^*;[8!M>+N(5V#;KE M@U :="/' E^*S')P"LN?C[_((9;9*XF5Z_0DM[2$%JV9ZA[K]O9T_L2,]^*@ M)G!91"5_V:<1EBG9YK#;6'SX=[N(#)]<@OXO<&C8 [J@&'Q3"[2L1$TM?P-0 M2P,$% @ 2H%M5T6#XC']"@ @(8 !4 !E;G9B+3(P,C,Q,3$S7VQA M8BYX;6S-G5UOX[@5AN\+]#]PW9L6&,>)@Q9(=F87&4^R,#:;9&//;-M%L: E MQA%"DP$E)_:_+RF)LD3Q2$J*DIR+&8_X'NJE^)BDOHX__KC;4/1"1)IP]FET MQRQ[3L\GD]?7UR/&7_ K%T_I4<0WPRI< M9#C;IE5MQ[OC\D\1_I$F[.E<_;7"*4'R>+'T?))4IHH$D;EMD=!'NQFJ! 3%3]A9(TS$JL=G:D=G?Q#[>@OY>9K MO")TA)12\@&VZZQ15QDT<6WVCHB$QY?L?:[-:$_VY7='9/]# ^KQSINPY!FF M[S)?CW1N^X:\[X@?XMP?:3G.D_<=Z5KD_\5VUK;\YL-K/ZY4;;R6GQH6R2Z3 M$QB)M4E51<<(G.\AGQC*NJO:>=2HEZK1G(MVV]7,F->9DNAHS5\F,4EDW=-3 M]6&L/N3-EO_Y8\;E2N!BE68"1YFN*6_&IY&E?&):4LH+H7UA$?4TKE1,(BZG MIN=L3(O#6(0_"+ZQ[K9L-;<4_D%757QQ6.0N *,-F2 IWXJ(O*E7ZFZAHU0Z MVE"I4$LJPL9?%Z,?<@WZ7:O^\W%RJ,5!1\LET'9#6+:4-5I:T"QVUP8Q@"]ZZ&_T[8Y%UC%04 SQ"$X6]2#4!7EB:,+QK:8WI-G+KKP:)SPMVUW\5.)@ M$3(=#J0H#T,JSA-)M=L0/0RUE*[I :R:W!BRH(BQ>P-9*>0HU_N'Y)+%@Q"I M='X ,6S:\2A% <+1=-:'AE3[!.,J22-,"R]70-4#S-0)I[N9KM9$6%I7%OBB@W( MG&;"+ ^"!<"4R4 A0TJ'"J&7GM=W"5BF'F($FV/*W!)@-]FDH*D)B 2K,8"& M@S9_IM0+$3,Y,@E,YRPFNY_)'FQ72^>6"FQW60&$ >$3K=#@" 9A)I1/D&:LXB+9UY[W&'&MW( W,]X#*]0 M>J+<0C6H"4VT.D," FR(3P"S1NB'XID4Q-5[/'D%2-7@A;B+.)8'*BW_N4X8 M.0';;]6ZI:O#;I,IBS @DF!W #^E\H/^@%0,NF6A0#-]0U.G_J&9#H5F&C0T MT_= LWSE@4!S^H:FGOJ'YG0H-*=!0W/Z+FADQWL=:V;RXZU8\E?;P]F@T@LR M;:M68 ZR\'!I>>N#106H]8P*\8E)OK"Z%7>"OR0L@I?,D-P+,(!I*S6&-CQT M[ ;[^*D6Q#K.ZUA3+,I[OR1:YF>4:9JT#S&%)CQ(FL9Z!Y="[1.).YYFF/X[ M>>X\$;>+O>!A-6R%I*$,#Q6;O3Y@BA@D@WR<6)>XJAL:UE?)C')WKP!;;!U> M :X5!@&!S5'[%>#BZDDABY#N<[3U7B582*U#]^U M,F;+2OO\MB>&P1TKGJYTZ;N M<:LHB-[O($V2R%ZHBT"=;"Q)MY?RX M/YFNEDE&;2>7;8FS.0DP5\U(1GD0; "F3!;R,L0?T,GTKZN_(1WEN/MO^%)@ ME3QVL=^L. 6R3UE5KB#HL*@YL$B"0 'V9=)PPU$I18761W:JAEE+FN;Q0&T>DV1ZTO?Z.O/0WYE[OH49HBP L)=IGKH=]FTAS^ZYH@$.@PUCHI M*:5(:WV\D'"8LM;]BX"UMT7 NF<1L YQ$; >N@A8>UL$Z-T6*4+DN'2[HLD: M \D).]6NH>BP;/)AD0:%"NP/'#.J$'2(<9W1,D]QIM+SBTV^_ROYP=)*0.8J89A%":95>D3;%?'^ M$&>T##1?@=.C#X.A829;.!5A.I=A%7A(=>GZ4GKQ ,9OA-*?&7]E"X)3SDA< M7$NQW2GJUKM]8J;'=O.A&4 T"ZR1U2+K.)WA\ &0G+'KVMW MFC;>VK9J V*FTR#T#G>9\^.P-BZB/+UBF1'U>Q')"_F",UQZ ]L+R5V_5-EE MVGR;TJ8-"*%.@^#[DU6,2A6#-5/>4L:(F5QJK7G'4^*&RGWBF);%=NZ82A(0 M'C9?'1ED!-):+RPL-IC2S]LT822%)R)#Y98%J\4F"PU)0"S8? $LY%*DM5Y8 MN-P0L9;3VT^"OV:/97Y6L&V VBT;G9:;C%BE ;'2Y0]@1H>@(D:GU/4#S^Z0 M4+S(L@BWU")UC UHUF"FI0L)&,AUCRYS@.1BO29S:B> MW!Y>XC5$CE?&%H/&PKBF"((1T!:T+*[_5H"?W'G;%4VB*\HQ?)6EH7&<,:]M MSTB6=Q $1$#;%90B+Q>B7.FE_S]C]B2VSUFTOQ,\(D0]9956HU7?];>!T6Z9 M>5.3FC0-"@V(L[?X!0@\5(%J=7RHS5@^+^:IA\95-C<>/2T>L3R M]LL53.H M- 9?!>\,>@'5 2C6K2G\[/TD 60Q)_W M]^2!"/7>P9+LLL]R1T\=9Q@#8EV?O0UNCGDRUQL8!(1O=0N=ZJ6H7@%:J6?$ MRBK0[ZH2E-=B^_WR^J9K^4ENUIOD7RN<$KGEOU!+ P04 " !*@6U7!+=, MO50' #35P %0 &5N=F(M,C R,S$Q,3-?<')E+GAM;,V<77/B-A2&[SO3 M_^#2:T* ;MMDD^XD;-AA-KM)0W:W[?1!RJH(D:J MM]%7PC.W10X9IRH:R'3!J:'VBZ+A\^C-2>]T$K7;@'J_4I%(]>5AM*UW;LQ" MGW0E] MOM+LLN7:W32[[)](->OT3D^[G7\^W8[C.4U)FPG'+::MLI2KI:I<]^SLK)-_ M6TJ/E*N)XF4;_4[9G6W-]EL6T._T1+-SG7?O5L;$Y&&O;2;R*MQ_[5+6=IO: MW5Z[WSU9Z:15PL\)*LGI YU&[J^-WK95*NSNQV(7KX[[KC.0=H/M:%YJKNCT MLF4U$UMYK]_M=ONNZE_W1&:]L/NE9FZW:D6=O687BFHJ3.[TUF[8*T)7QNY- M-"DKAK./=[WM#51!M%8E/6Q,F$\KS^[U9S(.DTT*N2Q*.M ML;I3^XK#/NW&[$K%D50)599U61=1\5ZDCG?+C:*S(,I6U([GC&^#/%4R]='9 MD)">CNZ"LDTT0_/*MI^X/@PYF57C/) >78Q@%:ZP2+ZGNI8L87C4@-V3PGD MVT/E6^&M8%SQ%@.#[F"-%T"U2!*Z$R A_H NI M:L#O*X&\?\/D7>4-"?/?&5&&*KZ&D#X2 V&_P83M<8C$^U$1H9GC P%^K 82 M_QWUPL/C$0GY>$XY=PD<$:"]O$H/Q/X')G:_SU< _N;9G=_MJ07.?J<($/^? MKP7_D5ND"-S;;% F]I2N .R/Q$#J9YC4/0Y1>=^(!$I[*P7G/_BP#^PAH1XR M'1->]&AHM^DP[@HY%#E*SEEK$Q7[OY0H,/0=,10Y2AI:8[%AX(-,J;W.!$<5 MOQJ*'"4!K3/9,/,;89A9NSO^G[-T\N/&Z3[K8Q64,4K2Z3.%PK:\TR",>Y 1 MXGNHA#)&R35#YE X#ZP?1?A()'3UD:Y#H(^D4-(H.6;0'@KJ>\52HM9C%MNK<(E#U*6@FRBQ*"D8BE6LB=V\4# MF=GC<3V027!(KRD(#0=*OOD"ZRA!N4H2BTMO_MPR0;NA4%3*P<^(\ (0L/E* ML/=>AKT'QXZ2A];:?"78^R_#WH=C1\E%:VUB8A_8CW?J42X]3Z"]8BARE%RT MQB(F\/Q,>-T\8NT]]'>^!L]@ M0QE6#VTTC/&;8L;V8"#3-!.;>S2>IV(>*10O2OH7M-X6H M&.'5G*MT4,@HR9[?6,.$[Q5UD:;VLCN?Q^46&JB[Z=0W\H;T4.(HN5Z]45SR M(ZTSJE[*OZ(4- HH:1_4=-/C#(TS.^RMN[W)HULQXQEECE10UB@IG\]4PVP_ MRT=%W$J]\3J=2.Y?'E(IA!)&2? "UAJ&O->/:KP'$BA8E,RNT@[2F'"SBN=$ MS*A_]D*U$@H8)=,+F4,;>V>@L7?VPK$7)>/SF4)B6\P-MT?4W82S&?&O) L6 M *^SP20>L-KT^KU\R8];PZW2O!]#^Z$:NT<*!8ZS1#)DKVG46<(,38HN#9D@ M(K8IU79=FR<[KR\%#0#.&DJ@:93;^]\HYQ^%7(HQ)5H*FA27^J$[_-XBT"@@ M/D.LL8L2@J^29Y:2RB>"*L\QX)%"D2,^._38PYE[64QJWIY[BI=UA(C[2D#! M(SY$#)M%FI]FJ.LS>Z;OB2&;'H;X^TI ^2,^4 R;19L_KP;VQ#.3X6?F!T(H M;<2IL)764""/4\+Y=::9H#HXMAP(H9 1Y[Q66D.!?)-2-;.#V@DUBOW8AC-Y&B.).+A"@/ M]9 >RAUU8:7?:,/D[\R"1@$E786:QCFW[JSD#YY: M]W10WHB):94QG#53V82S>,@E"5Z7[\F@?!&ST I;*'BOB7A2V<+$ZWLE8TK= MXQ.]/=H "1&P FA($//3%Z' N5T@T]0M)I+QTWAN3>N[S.3O+K7]"]XT"):# MA@9S$2? .-)5D/ZQT(LFU^L'.J7*35-XI"MS;1MZ"E\4 8I#XX/Z1B$PAHHP M772.?-W:#>[MM,4W[I=[ ZO=\C]02P,$% @ 2H%M5S8"O6VD%0 R8H M H !E>#DY+3$N:'1M[5UK<]LXEOVN*OT'K*^X%0%&/..D9QV/%FJH>VR(%7 #W<>X+V?VE M]_[X3;.Q^\MA]P _!?UOMW?4.SY\L_O8_<33Q_[Q[MZ'@S_$>>^/X\.?-P8F M+5Z+K?=CV0(YU,GG]M8'Y7:O_4HZ.C3OQ/G9_L_ M;ZBK5Z_:6_^WN;G5^3,;;HCN<>_GC8V[N!/WZXQFA2!2::'RFY:"] (/HV9C M3QL;:95&&.%,928OK.B-=!Z+WTJ98V*QO;G]1.R;',]DH81,8_%6IS*-M$SP M%5LFA;U_C!Q@_YG)7:O MVO9%VGO=O>-#L7]X?'Q^VMT_.GGW\\;F!O]]VCTX"'__[>.YU'$QHE "PVSNXH0/QJ[AY MOIH3@][!"I'^CU?/7[SZCK3?)+&GN;*DLV-'(BG,K.PGVHY4+!(E8YT.!2M= MT*@C0:_+/!J)6-DH!SC!XUA=J,1D8[S# ^"!4BD]&:MB9&*+:7.1FK0]DDE2 M1CHU0SR/6B)596ZR1-K"?2+BO!PZ2B*,I&,H<2MT*KP)>)#;SZ79L0(Z!RI' M.(TCS*#^>@$EH0J:OA@I4>1*%DP:WJ*?, 0C)9,"2]"6Y"Q ME1*(=[F<@JZ/G?...)7$B.+AQ_/3W@=Q8CIB:ZOUXMEV:^O)YB.1Y>9",Q:+ M$JG'EF3 \3N;!ZM9, CAR(+\8,9Q(YF/9<3:'?S-,@ @-BX3%B.'RJ1P2W"4 M,)#*^^8*TE.0K0+Y%WC[PH&L(I]DA1.KOK0+MNP+AN,Q>U!O[KX;^!77^VX2 M30[X7OO)BR=KOWOM=]]]C;] >J6V?PA]O?FB]?3IBT= +Z27@>))92\H:ONO M:&J8 'I@!=Y*]%\8V%&S_[3-.CLUQ4@;4-6V91];592DP:8BMC%4A^_ R(V+. M@4X<7*;V9U8H"V'26>VVO!G#HPKR(W M:_Z]Y_S[BQZ.$LJ\+F5AF>IQC7MC-88V+8CAP% FQR,XD?)"ZD3VH53!L<3 M WF!9_VD8N/ W:2& ]A:\]V]YKM]6-!$55R'KY0#&14EZT:H/<VX+=A+L<_MCMU ]EFO]8;/=?N^[VSHX-WAZUF MXSWP6Z<%;'>AQGU M2W8+4XP/TAC:4<[(2LA:GGIECA*HXYX>-(]/^C^]EH< MGOR^]T@\?)#$E+BHTAC\%S00&TO_D%A*IA/_\!'92&BG0D6CU"1F"!<]$A$5]F<6RH8(/N_VFWQ5JLD?@WO8JAV M,,#GDK@*7Q3M=M"&!T>_7ROX;BGMOBD*,WXMGM.*O*,;/MM+9/1);'6>86,L M %R,Y4W][;I_/>]_^XF_Z#C/.=B++O_41BZQ?+-;GZ@!?^-Z[5^;;[JU06,& M;;G[&+OVK1O8APQ\:O<5V!%T9WP4?E-!(^\HR+I>^\[HU$#5Z2P=M?-^3 ?N MSGA%^??.$^V4;&^DFHWE^N526NBL#-\W,7UH00KEO.'Y.XL,#<@JRI104TH" M7EIQJ8(=AVZR4,,$*F'&"^W#IL5(0L94?N&TM4I'4'JL?)N-"YF4BJ:B$6,] M&*B@ 4$*XT(2^X;\UF5>E*4#.:(GK1GV ?+B&"%&OQF)Y6]1$; M3+:@X(2_#\40V3U*?X*M/HD/ ]"C?'SF475N"X4#WE8N%"A1CHU)A"R5Q43R$&=N@>^4P& M[5992+>^F;H58!FJ?9EPDA)#FJS08XZ_>=Z9AMAP3M.$24=\P 3J*H-0N4FU M$TD7,;S422*&.2L7SQB.$DIPXJUE^P!9&^EH)"Y-F1#)H"LM2=ZA<2(8+;M, MKU0 ,NS/H,Q)>1!R(S^XU':T4%_CX2PIEF%.D4*VB6$+RE0#F'2\4EDU0["* MUNL@[S0;3F$3]E: #)5!P_D,1]?@9DZAIV"2WYZRLA[)"VCLD;F,F-_HBZ'0 MBU5!*#.9>+CN<_6N.J79Z*N13N/ERK2**[=<=CU(-I>4!:W *LB5G?E/= K# M0(J;S)PJB"LQ ID,+AMPY0&!QJ#4F@WM)*56WN+&7E+NXE=6,SE8 XXI9W-& M[X)0#DFV:R')RAD*ZX$=5>"P7]1<[9?&B5K"-AFWEC ",ZP1&VX3^! M,EH&F^^Y;X<)5,Q, KVD(YWQ$X]F^!2@%QV_T2Z0C%[5=;C9\*(.. M&$MZRA46\ !E/M7#,H7/#(59Z&'0OR08!W1B-9V]5C>W#I:[%@<(91),B>G_ M"6-&"21&LK;, \!D)Y[D$QBYM407,;9.K!$1L(>,* KVE\-W(0H&[F+1F FD M>541YF@V)$T/=L1J4J5BAP.JV&RNAH1A#*0Z GOG'@V+OAJ2BL&+N27)%Z,2 M\TQ)+S@F5T7M6'YE*."KA8-]G*+98"#JH?4C0OW<'WOQ!:LJZM-!AS48P[\ M4/33JV6',@U0@^+ZPNKD+?LL7)A(*9])7Z=SZ++"*'6]@KHB,E_V#UX?_B(1I$3.WL^;KT 5=#3UNO8 MZ:[1BJ3C_3!ZH:J<5>5?X>NDL3%] MPS/1/3D09X?[AYC@].S#N[/N>_'Q]*#;.SR_^0Z@IV_WJ=R>O-]*M\U M/_X?,NG7)P>WU\G!^Y@<7'FN_L&!ZCQ<*!KI+!!(4YBR$'W% MX8>2,R4NW$[B$H6"B,\EIR,=W6F1 XQ0S)\Z=BB0?FL-#6M6_@ZL[.HQ@L]J MP*NDL%PU!O/@,#>7Q!]'I[4;&GQ-5-W'S70&+SA5M1H6SJY8EQ[-?,'3+%PA M <&@54V+CTK=1&%+O1'X_GC=/[A_92G>-*4NN-KM_4Y[IN#UP%1OQ1I,;=U?']K^J8OZ7#Q^O5 M^JJ.E2M1X/K,MT6+3245A'NW,]8)FSFF-L/@3"$)^D];'9I(NFX"F;N2.,D# M\]OTSG;G^68U:ZA?I2F%F]&_M/TJO$3U_1RYS#5.9/)U&IX^KWT4]N>%'C82\&KEQ6+4 ##NAX"5X\\*R2! <&;,2V+ M#%5_XCF3F&9!%.9XDIM81C(=NH(*JOQSU1J)#N63?9EPU,2/!V7JQUMSUBT0 M3>7!V/AEW$(\Y?N9Q8A#U]:5C/,O% 6[D DWO=#)/>ULOUB?W.TBD6[?E% , M/K:YAARW0_32J^SG+@O0=K[S7WR_QO]F8VGG?ZWA?WH+P!<:_SOBF'M;AMRG M I%V[6%S?40S[9[P6\B]:R6SF)_1.7I>.4P+5RS "W29BKBBL#9FCI?,4_FL#-?M0=X2(DWGT=H MA2[&[5H7(QU-KBTW),RFXES>N'!Y/1?[<&7[BYFL5I7*JD@@-O![QE=]T?=< M_T)H+ZVZ86>[4*O+*5QB(ORY])B_D VLD$U&_,5 MD2U.I$O?-_@] ME;'LB+PE=?7MCU9U[;= MQ]JVN\F_U]Y7>O=I?^NZ4=O'AIJRH,SY_@3N;UW!!:TD_NN--/54LB7+E5/M M5 <@M7/&^7P2=S["5L<3;J"8>5PS$VQQO+4:*YD&E]PEB/DF.T"_W&&A1%Y: M[B:D]L':'.YF!6ZH+ MJ[03Z8 \M#Q\ ;O&4T,P=NI6@3J'A?KT"_OK,IP.! M%1OT?U/?$331N; S"@(CP0 M-C\43/E8AZNV; E0 @CJ.V&!'%(;NOS\9Q[DV-IM7OY); @.FL*_474'AL& M1(Q5\?SGVE:X*3QJ-ORS?@GX4-CYKU@JF >F7QB+VJFI2F;A&Z3;X80O#D78 MFCKWYSZ>-H+;BJ8E*YV^UEKVCN':#==JZZZ7X:J=R-U>XCM6"8Q6?!PJ\\ :A-S+A)K=W0\" M7W3KC#!11*W..?$.D"D1'C,X^Q+?83".W%+?9YW;YUAS1M( _C@>S#LSL 3S M9%KA9ND)9SG@TE%7/!2^Q;Z $TGVR?#35WSXWEL_K,LRI;"PKM-IVMP+ %Z. M,S?N&)X7[?*\_& ;Z#JB!$]JR=Z]%RUZ&$:.'T M/B,\>TTY-/BFY 2 ^X#4[:!,Q'SM&./W+MT4 :,@=P)',-FNL(>=5-ZO^961 M_SY_(X*%^,@+H\DA3J@(DJJ!C$^]A5WEG&LWT3 L2>H>;B#,O[<2#7?2=Y MY-5E)-^*QDX5[2ZE$884#TB]_\UO80\AP\Q6^2>U;(W5J)[C!V7*0A"*"L@5 MGN_GHU9QSL#*3--4?#KCL5K;X/L5+2V7 M3;5R]RPJDL>(+F@9DIR1@IJY FF^RS!L6CWGY*O%\*A0K!)WJM(OWSV96_ Q MW&F<#6>010ZIH+Y$0YF#C!?EF)T%F6( V [L'\REKO'M3(RG*F&CN#V6Q8$/ M+XF@O+J]B"5\:%R-"9!%GNYX'<,3N5-O-JAT#EZUNQ@!-":366%TYHLD#V!A MH(LJV!(96[A+#UR!-(0M1!N ]9BA\,M-06%0-.N';W>BN,7_S96Y#*1ZMZ>R!'&<[!_ZV-.LN:^*=3JI;EN@R M.3L-2:03BKA@'*QJG!%F,@O]I*3JW:;Q$7Y)@S@>&M)F?FDO F%A^E0-I=M@ M/SM-,L]G_=+R71\@8YI,\K=[^FK#'R(X<=>)[C8;%&8M;2B9YUM!7#DG _)% M0PDM8C]9?X^7MZ?L%X0JZ5X9!856B*9-[ ^+D;AUR=]H7FG9M< T?H8A?%^SJ'2RB6 M.1.V"VIKBCWY/"XQ!Z&\2&6,QZJ"<. %^&5KF;F=2 B5:D,P5C#JL>(A*'?1 MEX%W<*9\;=L*+F0EV;ZG^W2];$QA/VJY&D([=N,+RI]8=VOYBBWH0*9:)+AR^?;CYJ-[:TG[:TGKUZN&/5QWVWZ?Q>>N2@KM6)K M6$EAABI]3^G.M1Y=Z]%_NV]-6C5I-MY'!]0B%J\8]0^?/WT.!?KLQ8OVRV?; MFRM&?32.8M[U;].@=[,8_SI,>GUV_^F.^."BT*_%L;3%\F3_.J__E;S^;=X5 MT]^U?BR-*_>X[_0U_N=^]QSLHC 130X1X%=!D5 M'-'9V?W%TTD:TD->DW0$_.N_ZDX"!(*CKLP0%^>!I+NKJZJKZ]6/'/]O;!KH M@;@>M:V/&2E7R"!BJ;9&K<''C,_ZV4KF?_7=G6.=03VH:WD?,SIC3BV?'XU& MN5$Q9[N#O%2M5O-C7B<35*J-$^O)A8*4_WIUV5-U8N(LM3R&+95,&QG4&JZ& MSTNG5177H+&J_$G423&_!!I*M5F#^ M46. X'MN8#_\$$XE6Y0B.$N#$Z>4%RO8FW)<(POLCOJ$ F@A%Z.*+NFO!'N0 MA]*HHN]E!Q@[T\I]["FB8E@0@PK/7-L@7F)M41*KKMJ^Q=Q),L9A8:R!Y[)E MT/ P5JG5^7(ZK44LF&=4S:FV*2I)DE3,B+E%L :?B/\<,\H,4C_.!Y]0:A*& M$0>1)=]]^O QT[ M1BR6O9TXP&PU^/8QP\B8Y8,IF.?M\B'8XW]EL^B,$D.K MH1YA1ZB#35)#8VU\A-I-\ /?@%-C MO7POM& Q!//7@*GR7&Y#F$5EU!:"5RQM0GRV,0@'S-]D+X:D@H.0[?4A"H= M,D(WMHFM_>#!/B#@TKZ0H)L:X%M*,J+9$XX$PP?-F8$0UIO.."__)Q H4VP669)GMU-"I@=4A*@%NGFU0[0B%A8K- MF&U&Y5*N/*O!Z'_<^CE8_BEFOF>@ZUYN-D^-JD!=O8' MD.<95N <.\YS4/7-Q[8BL%7J=YWV;:NYN].[/;EM]8[S2OI(Z+4:=S?MVW:K MM[MSTFFBUM?&[R>=\Q9J=*^NVKU>N]M)%5UR2-;AY+TZ#"]QEV>[R-3KV0O%MWC*4^W(O$3=+M2;_@N1 9L=^>& M.+;+MGS_27R_]EW/QYSQS(9Z*D^U(:F(;!=)Y3WM [+[B.DD?>/!S1=1?9J]DJ/(ZFO3+W5^=*Z:3=V=T[;W5ZCW>HT M6KU]U.XTZTQ5L'$<&X@H08B+B#L(<\A*L^U:8C"(#$/@:8&+>!^ M2!^MR?.#8<4@T)MAP'-5+&06,N*[@S4M^OYBNN9R%=,4A&H;!G8\0"CZ+2%7^2F2N*@)SF*: MH&VIM@LF2"PX]A@H\T:PT-:PM16*H:@_:G]ZA/I=Z;5&AJ^%\F0P(XYK/_ Y M$KM]\FTAG]+L%9TFJE7R]E2J5(ZE,O/%#/XS]T46P8LV6Q'A#M=PD@$ M)$(T;T,4[Z)O$!![&A5A_I)[)9BQ\739_0!3.F\0%WW%OSN94ZZ-4B&?#=LT MJ>>E5Q*YT0QP[=BYK02F3P+;-[V P);I&/:$N"D5Q+B%?5HD9V8T+^+2>DJ# MZLW&.<$9.XDY8R>:YA+/"S\NJ46D9$?LLW;7*(TOV-T5_5N.6$*'F7HKV!^Y MNW-*;4^E8FO6/H)0\UVEGQ9'HOF#D9"31X*H5N?WZSMY>"*_\4@ O%*E+.WN MW *1\!?=NI@:J+-B$/:7LN,_HJB83)&L.>S:ZEU*Q8,WIJB8J?=\R@B2"X7W M+$JM),8WX->N>VN/K&2V'QP6+Q^_*?W?9?(6;)]UEZEWL&/P;6/)F?G:Y@HHEX2\DT7!M>PP; M?U%G=>I.Z9%NVRP,;GWU+2B(]9BI%TM2X?TL_'!O*:13+.0Y+HP2=;"!R)BH M/J,//+$/'@A Q9:&'JD#/-3(N\GA;S;.,#RS-97__KLB2X=',%",&,31;8L@ M2V1=]GG0;/@\KD#8)5@,T?)::S&<4%RQG$"UU5/HL*3JK$QI;]Q_Y12:[R-3 MWY.+U0_/G??1*MZEK6+CFI/Y5$*KZLJJ_:GD#>]>NX*WV _,\8*G9[8+TA(MBKIB18BX" =:%J9J'P5;5B#VYB81&=B+MD@LA78I MH'G]X_3-]R *GKPET@V=J$-0I#I!V'%<&^P>W[JBV&.D$,,>\5'BA7PP425[ M@?K4X-J5>J!J&;$T&#UFPP":OL&P16S?,R;(@SC=ZT]$R["!K0 -(GP/=US! M2$\7R7V Y*"K4E4V+<-Z)TWY&N&E"?1O-K;\G:[+OZ3U\4+N3*UDA-_&YKD MFT-=_BFX+[H ](A:IS=(+E8R$'%#YNZ\I>R^9EZ9-L6SS$!JW%YSZ8 J,ZJ%F5C/?K?U*Y]_1+;\>5?HO.PD1N47G<2XY3J@3WOC6=OQ"O!I32Q%1L8\_[L!WA M]S.+^0'M^"0FD>&Q+332*3P)UFB)2[1TN8IKW]^P8IMDN.@SD61%*,ED#\Q7 M*KT_.MV.^<=KSYXM]I.I<[:8.]>+!:R^+BG4B[FPXW8K(QA&P MZFA_I NBL&'U)1_CQXO'416W3KNOOC!&G.7G=F+Y&'\2'N!'Z-$1,NQI^#OJ M<=V$KK [).P90O9NHIL-1[IM:3Q&A;%2)DCEF\)X]T-P X@X5[NP88OR7= ( MPER.X0 -7'O$=![K.GP/%_:01OK4"FX\"?9&%,K1UJZ%C1'!755%M,?Y=G@D M]D<4RF(3-M.IN"S%X9>E\"V$0<0L*UDY 5C2#5A3J#QZGK6; YM+V4"E4KI: MH:#L[BQ(RJK]3L'!@ZC9N6C4"-HDJ[9O9MEHL<;#R>7+C.!SDEI/(//L?%8Z MQBF5PM7N\YVCJY01/Q(0J#84UVQT:1>J#GJ+&$1EH+5 MO[.#BFVLP8WD7()$7\9$"/B(0M]AHP04RC@PE0^8KO\9[? QZ#/SX_U3XTU7D6_#DE6ZFU&S-T= M.5>0T0WQ?(-YW !U'>*&*UG\%.39U*@U;+"RO""W[H,[(;F@(V%J@*WW+8V+ MLNW6>,Z27T^:0C7T4ZCI6KL[2U>W[J/PC@2T=$4"1'F>#RX)!N^$>!ZX,N > M@T,4^"KBC"6*KB@BR'?X7;)"++!E 2&J."<$)HB3-+4X2UW1U>!@$J^(73%_?\C'!P*[JO2$^ CP]^LZOQ5PPB MX62?$PN4D0&B"OZ['WC*ISD1X4>GU?:%D%%K^I(]GH\0$A1>QQY=V PELS:S M,\3SDL1A8;:[$Y.V>6]=P.5J$PFMZ>G8,$0>_$/E_0 F4B[N 5 MHZ'P2$XH#WY(D3#.=I DP#>\HU>-(0X\4?7P .-6,6R$0U+E"UDSMZ,7B5'@ MCX3SU=LZ(1M+S9[V@>NNZ3B]+56_;#C2N7EIS?N4$H/$Z8G:PS*UTG"+7BBL M\V^T^R4_'7M1K:UI&\[3PR9MR!GN=0IJ /0G;.Q5ZDWBJ2YUENZK3<4VFU2M MSV^1_8=*%H_>4CM4;X\L1N'KC%6)\@KZ>WEQ.\Q!K/F6Q]ICDZ?4G>;O^]"[7G]:YXKTYF*7T3KQ>^[QS MJ&B<3G[2S<3]H] MI/G&!*G8YQM^Q') <)MAF/?W@$@HL(.7P"E$QT8?*9/@]CV1[@YK\'4IGZ?- M!3SL,]UV 7WM?>Q53&>J+'U>YE.^&["#/_Z8D5_!Z07$I35D1::OC>0(S[TZ M,GQSY";G24(Y+*\ZN+>Q[GET'BVE>)<.?PGBFR5\ZZ:?O_^W%KU_955,O]E1 MXNFD]M/RRFO/']-ZWLL')'RR/>+HZ-97A_P]/W2#562JU,L6V3ED R$+$(PD M;2ME*1BX5"';T"D)7X+8FKY]HRO>OK%"WE*3E-L@_)XXS["8+"P>H:Y8HO1J MZ)+?TK_-'?X@=[C-[KWYS,DKMC;A4SRO,].HQR6V1]@1XB>.:VBLC8]0NRE^ MN2]43N_%X2WQ!H%@%$0[\FE\]NU+X6+T[>2SWLI_[D[&9?Q\]?AX\M@8^-F]LID!1< MJGXNZ<._#C^;S;;TFW\UH,5QFXTM]ZM4['M-=61?G9I_WET4AU>?35(]+VE? M3H?#R6WG0N\-S[M7!\; TY6;+Y7\)VLHGTDZTP:'?WY1/AFXXP^DA_SWEO7U MH.<0Y M4'. )P, . + 1 " 0 !E;G9B+3(P,C,Q,3$S+GAS M9%!+ 0(4 Q0 ( $J!;5=%@^(Q_0H ("& 5 " 58# M !E;G9B+3(P,C,Q,3$S7VQA8BYX;6Q02P$"% ,4 " !*@6U7!+=,O50' M #35P %0 @ &&#@ 96YV8BTR,#(S,3$Q,U]P&UL M4$L! A0#% @ 2H%M5S8"O6VD%0 R8H H ( !#18 M &5X.3DM,2YH=&U02P$"% ,4 " !*@6U7S JO&]L2 "6G "P M @ '9*P 9F]R;3@M:RYH=&U02P4& 4 !0 V 0 W3X end